Anthera Pharmaceuticals Company Profile (NASDAQ:ANTH)

About Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals logoAnthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ANTH
  • CUSIP: N/A
  • Web: www.anthera.com
Capitalization:
  • Market Cap: $14.72 million
  • Outstanding Shares: 10,906,000
Average Prices:
  • 50 Day Moving Avg: $1.35
  • 200 Day Moving Avg: $1.28
  • 52 Week Range: $1.20 - $27.36
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.41
  • P/E Growth: -0.04
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.40 per share
  • Price / Book: 3.50
Profitability:
  • EBIDTA: ($50,120,000.00)
  • Return on Equity: -1,096.21%
  • Return on Assets: -205.57%
Debt:
  • Current Ratio: 3.29%
  • Quick Ratio: 3.29%
Misc:
  • Average Volume: 296,334 shs.
  • Beta: 2.68
  • Short Ratio: 6.88
 

Frequently Asked Questions for Anthera Pharmaceuticals (NASDAQ:ANTH)

What is Anthera Pharmaceuticals' stock symbol?

Anthera Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANTH."

When did Anthera Pharmaceuticals' stock split? How did Anthera Pharmaceuticals' stock split work?

Shares of Anthera Pharmaceuticals reverse split before market open on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 28th 2017. An investor that had 100 shares of Anthera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were Anthera Pharmaceuticals' earnings last quarter?

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) posted its quarterly earnings results on Wednesday, August, 9th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.09) by $1.12. View Anthera Pharmaceuticals' Earnings History.

Where is Anthera Pharmaceuticals' stock going? Where will Anthera Pharmaceuticals' stock price be in 2017?

5 analysts have issued twelve-month target prices for Anthera Pharmaceuticals' shares. Their forecasts range from $1.75 to $10.80. On average, they expect Anthera Pharmaceuticals' share price to reach $5.89 in the next twelve months. View Analyst Ratings for Anthera Pharmaceuticals.

What are analysts saying about Anthera Pharmaceuticals stock?

Here are some recent quotes from research analysts about Anthera Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. " (8/25/2017)
  • 2. Jefferies Group LLC analysts commented, "Following narrow miss in Sollpura SOLUTION study in late 2016, ANTH has included key learnings into the Ph. III RESULT study, to start soon and data by early 2018. Decision to discontinue B-mod in lupus is not surprising due to negative CHABLIS data in Q4 2016 and conserves cash. With $21M in cash and two ATMs, ANTH is positioned to fund operations through RESULT data. We expect shares to remain range-bound NT due to few 2017 data catalysts. Lower PT to $0.80." (3/6/2017)

Who are some of Anthera Pharmaceuticals' key competitors?

Who are Anthera Pharmaceuticals' key executives?

Anthera Pharmaceuticals' management team includes the folowing people:

  • Paul F. Truex, Executive Chairman of the Board
  • Craig Thompson, President, Chief Executive Officer, Chief Operating Officer, Director
  • May Liu, Senior Vice President - Finance and Administration, Principal Accounting Officer
  • William R. Shanahan Jr. M.D. J.D., Chief Medical Officer
  • Brent Furse, Director
  • Christopher S. Henney Ph.D., Independent Director
  • Brian R. Mueller, Independent Director
  • Philip T Sager, Independent Director
  • David E. Thompson, Independent Director

Who owns Anthera Pharmaceuticals stock?

Anthera Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ZENYAKU KOGYO COMPANY ., LTD. (3.66%) and Vanguard Group Inc. (3.38%). Company insiders that own Anthera Pharmaceuticals stock include Colin Hislop, Debra Odink, John Craig Thompson and Paul F Truex. View Institutional Ownership Trends for Anthera Pharmaceuticals.

Who sold Anthera Pharmaceuticals stock? Who is selling Anthera Pharmaceuticals stock?

Anthera Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Anthera Pharmaceuticals.

How do I buy Anthera Pharmaceuticals stock?

Shares of Anthera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anthera Pharmaceuticals' stock price today?

One share of Anthera Pharmaceuticals stock can currently be purchased for approximately $1.40.


MarketBeat Community Rating for Anthera Pharmaceuticals (NASDAQ ANTH)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  337
MarketBeat's community ratings are surveys of what our community members think about Anthera Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Anthera Pharmaceuticals (NASDAQ:ANTH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $5.89 (320.54% upside)

Analysts' Ratings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/19/2017HC WainwrightReiterated RatingBuy$3.00MediumView Rating Details
8/11/2017Jefferies Group LLCReiterated RatingHold$2.25 -> $1.75LowView Rating Details
12/29/2016Piper Jaffray CompaniesLower Price TargetOverweight$56.00 -> $10.80N/AView Rating Details
12/29/2016Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
12/28/2016SunTrust Banks, Inc.DowngradeBuy -> Hold$48.00 -> $8.00N/AView Rating Details
6/20/2016FBR & CoReiterated RatingHoldN/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Earnings by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)
Earnings History by Quarter for Anthera Pharmaceuticals (NASDAQ ANTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($1.09)$0.03ViewN/AView Earnings Details
5/10/2017Q1 2017($1.47)($2.03)ViewN/AView Earnings Details
2/27/2017Q4 2016($3.25)($2.88)$0.10 millionViewN/AView Earnings Details
11/4/2016Q3($3.04)($4.88)$0.18 millionViewN/AView Earnings Details
8/9/2016Q2($2.48)($2.80)$0.15 millionViewN/AView Earnings Details
5/9/2016Q1($2.24)($2.32)$0.15 millionViewN/AView Earnings Details
3/10/2016Q4($2.24)($1.44)$0.31 million$1.92 millionViewN/AView Earnings Details
11/6/2015Q315($2.08)($2.32)$0.31 million$0.73 millionViewN/AView Earnings Details
8/10/2015Q2($2.24)($2.00)$0.29 millionViewN/AView Earnings Details
5/11/2015Q115($2.48)($2.24)$0.25 millionViewN/AView Earnings Details
3/16/2015Q4 2014($2.64)($2.56)ViewN/AView Earnings Details
11/14/2014Q3 2014($2.88)($2.48)ViewN/AView Earnings Details
7/28/2014Q2 2014($3.92)($2.72)ViewN/AView Earnings Details
5/13/2014Q114($4.48)($3.12)ViewN/AView Earnings Details
3/12/2014($3.76)($3.84)ViewN/AView Earnings Details
3/26/2013Q412($1.20)($0.88)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Anthera Pharmaceuticals (NASDAQ:ANTH)
2017 EPS Consensus Estimate: ($3.59)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.36)($0.16)($0.26)
Q2 20172($1.08)($1.06)($1.07)
Q3 20172($1.24)($0.95)($1.10)
Q4 20172($1.30)($1.03)($1.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anthera Pharmaceuticals (NASDAQ:ANTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 27.26%
Insider Trades by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)
Institutional Ownership by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)
Insider Trades by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2017John Craig ThompsonCEOBuy8,550$1.32$11,286.00View SEC Filing  
9/7/2017John Craig ThompsonCEOBuy10,400$1.43$14,872.00View SEC Filing  
9/7/2017Paul F TruexDirectorBuy5,000$1.34$6,700.00View SEC Filing  
11/13/2015Colin HislopinsiderSell12,500$5.31$66,375.00View SEC Filing  
11/11/2015Colin HislopInsiderSell5,000$5.38$26,900.00View SEC Filing  
10/12/2015Debra OdinkCTOSell1,205$6.15$7,410.75View SEC Filing  
6/24/2013David E ThompsonDirectorBuy12,500$0.53$6,625.00View SEC Filing  
5/31/2013Bogdan DziurzynskiDirectorBuy1,250$0.59$737.50View SEC Filing  
1/30/2013Orbimed Advisors LlcDirectorBuy712,500$0.66$470,250.00View SEC Filing  
1/25/2013Orbimed Advisors LlcDirectorBuy220,250$0.65$143,162.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Anthera Pharmaceuticals (NASDAQ:ANTH)
Latest Headlines for Anthera Pharmaceuticals (NASDAQ:ANTH)
Source:
DateHeadline
americanbankingnews.com logoAnthera Pharmaceuticals, Inc. (ANTH) CEO Purchases $11,286.00 in Stock
www.americanbankingnews.com - September 20 at 10:22 PM
americanbankingnews.com logoAnthera Pharmaceuticals' (ANTH) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - September 19 at 3:52 PM
americanbankingnews.com logoAnthera Pharmaceuticals, Inc. (ANTH) Expected to Announce Earnings of -$0.90 Per Share
www.americanbankingnews.com - September 17 at 4:20 PM
reuters.com logoBRIEF-Anthera Pharma surpasses 50 pct milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis
www.reuters.com - September 8 at 4:19 PM
americanbankingnews.com logoAnthera Pharmaceuticals, Inc. (ANTH) CEO Purchases $14,872.00 in Stock
www.americanbankingnews.com - September 7 at 8:30 PM
globenewswire.com logoAnthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of ... - GlobeNewswire (press release)
globenewswire.com - September 7 at 3:54 PM
finance.yahoo.com logoAnthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis
finance.yahoo.com - September 7 at 3:54 PM
benzinga.com logoAnthera Pharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference
www.benzinga.com - September 6 at 8:54 PM
globenewswire.com logoAnthera Pharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 6 at 3:51 PM
finance.yahoo.com logoAnthera Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference
finance.yahoo.com - September 6 at 3:51 PM
seekingalpha.com logoAnthera Looks To Redeem Itself After Failures - Seeking Alpha
seekingalpha.com - September 5 at 10:33 PM
americanbankingnews.com logoAnthera Pharmaceuticals, Inc. (ANTH) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - September 3 at 10:46 PM
americanbankingnews.com logoAnthera Pharmaceuticals, Inc. (ANTH) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 30 at 8:36 PM
americanbankingnews.com logoZacks: Analysts Expect Anthera Pharmaceuticals, Inc. (ANTH) to Announce -$0.90 EPS
www.americanbankingnews.com - August 30 at 4:04 AM
zacks.com logoAnthera's Blisibimod Positive in Phase II Extension Study
www.zacks.com - August 30 at 2:21 AM
finance.yahoo.com logoAnthera's Blisibimod Positive in Phase II Extension Study
finance.yahoo.com - August 29 at 4:15 PM
reuters.com logoBRIEF-Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy
www.reuters.com - August 28 at 4:01 PM
reuters.com logoBRIEF-Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy
www.reuters.com - August 28 at 4:01 PM
finance.yahoo.com logoAnthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
finance.yahoo.com - August 28 at 4:01 PM
finance.yahoo.com logoAnthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
finance.yahoo.com - August 28 at 4:01 PM
americanbankingnews.com logoAnthera Pharmaceuticals, Inc. (ANTH) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - August 25 at 4:10 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Anthera Pharmaceuticals, Inc. (ANTH) Lifted by SunTrust Banks
www.americanbankingnews.com - August 25 at 8:32 AM
americanbankingnews.com logoAnthera Pharmaceuticals, Inc. (ANTH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 15 at 4:52 PM
globenewswire.com logoAnthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European ... - GlobeNewswire (press release)
globenewswire.com - August 14 at 4:17 PM
finance.yahoo.com logoAnthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network
finance.yahoo.com - August 14 at 4:17 PM
streetinsider.com logoAnthera Pharma (ANTH) PT Lowered to $1.75 at Jefferies Following 2Q - StreetInsider.com
www.streetinsider.com - August 11 at 9:23 PM
americanbankingnews.com logoAnthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - August 11 at 6:20 PM
nasdaq.com logoAnthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results - Nasdaq
www.nasdaq.com - August 11 at 3:30 AM
streetinsider.com logoPre-Open Stock Movers 08/10: (HDSN) (GLPG) (PRGO) Higher; (BW) (QTM) (CBI) Lower (more...)
www.streetinsider.com - August 10 at 10:27 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: DryShips and Anthera Pharmaceuticals
finance.yahoo.com - August 10 at 5:22 PM
americanbankingnews.com logoAnthera Pharmaceuticals, Inc. (ANTH) Issues Earnings Results
www.americanbankingnews.com - August 10 at 3:42 PM
reuters.com logoBRIEF-Anthera Pharmaceuticals reports Q2 earnings per share $0.03
www.reuters.com - August 10 at 2:11 AM
nasdaq.com logoAnthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy - Nasdaq
www.nasdaq.com - August 9 at 4:07 PM
globenewswire.com logoAnthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 4:07 PM
finance.yahoo.com logoAnthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results
finance.yahoo.com - August 9 at 4:07 PM
finance.yahoo.com logoAnthera beats 2Q profit forecasts
finance.yahoo.com - August 9 at 4:07 PM
finance.yahoo.com logoAnthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
finance.yahoo.com - August 9 at 4:07 PM
seekingalpha.com logoAnthera Pharmaceuticals: A Series Of Unfortunate Events - Anthera ... - Seeking Alpha
seekingalpha.com - August 8 at 3:45 PM
seekingalpha.com logoVersartis - Preparing To Get A Lot Bigger, Very Soon
seekingalpha.com - August 7 at 4:45 PM
americanbankingnews.com logoAnthera Pharmaceuticals, Inc. (ANTH) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - August 5 at 8:56 PM
americanbankingnews.com logoAnthera Pharmaceuticals, Inc. (NASDAQ:ANTH) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:05 AM
americanbankingnews.com logo-$1.08 Earnings Per Share Expected for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) This Quarter
www.americanbankingnews.com - July 24 at 2:16 PM
globenewswire.com logoAnthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis ... - GlobeNewswire (press release)
globenewswire.com - July 12 at 9:29 PM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 11 at 8:50 PM
nasdaq.com logoAnthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis ... - Nasdaq
www.nasdaq.com - July 10 at 8:55 PM
finance.yahoo.com logoAnthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network
finance.yahoo.com - July 10 at 3:51 PM
nasdaq.com logoAnthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura - Nasdaq
www.nasdaq.com - July 7 at 3:22 AM
globenewswire.com logoAnthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura
globenewswire.com - July 6 at 5:15 PM
reuters.com logoBRIEF-Anthera announces expansion of screening in European sites in phase 3 result clinical study of sollpura
www.reuters.com - July 6 at 5:15 PM
finance.yahoo.com logoAnthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura
finance.yahoo.com - July 6 at 5:15 PM

Social

Chart

Anthera Pharmaceuticals (ANTH) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff